Latest studies
- Active not recruitingPHASE2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
This study looks at a medicine called PF-07868489 for people with high blood pressure in their lungs (Pulmonary Arterial Hypertension). It's for those who have already tried this medicine in an earlier study, to see if it's safe and helps them over a longer time.
Pulmonary HypertensionCzechia - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesCzechia - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveCzechia - RecruitingPHASE3
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This study compares two new treatments, brelovitug and bulevirtide, for chronic Hepatitis Delta. It aims to see which is more effective for people with this liver condition, helping us find better long-term solutions.
Chronic Hepatitis D InfectionCzechia - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DCzechia - Active not recruitingPHASE1
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
This study is testing a new drug called dostarlimab for people with advanced cancers that haven't responded to other treatments. It aims to find the safest and most effective dose, and see how well it works against different types of advanced solid tumours.
NeoplasmsCzechia - RecruitingPHASE2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
This study is looking for adults with Graves' disease whose thyroid is overactive despite medication. It aims to see if a new medicine, IMVT-1402, is safe and helps control their thyroid better than a dummy medicine. We want to find a better treatment.
Graves' DiseaseCzechia - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerCzechia - RecruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
Metastatic Colorectal CancerCzechia - RecruitingNA
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
This study looks at whether a special feature in a Medtronic pacemaker can help lower high blood pressure. It compares having this feature on versus off in people who either need a pacemaker or already have one and also have high blood pressure.
HypertensionHypertension, SystolicHypertension, EssentialCzechia - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionCzechia - RecruitingPHASE3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, called LUNAR-2, is looking at a new treatment for advanced lung cancer. It combines a device called NovoTTF-200T with standard immunotherapy (pembrolizumab) and chemotherapy to see if it helps people live longer and stops cancer from growing.
Metastatic Non-small Cell Lung CancerCzechia - RecruitingPHASE3
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
This study is testing a new medicine, Givinostat, for boys aged 9-17 with Duchenne muscular dystrophy who use a wheelchair. Researchers want to see if it helps reduce muscle decline and is safe to use. Half the boys will get the medicine, and half a dummy pill for 18 months.
Duchenne Muscular DystrophyCzechia - RecruitingPHASE3
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This study is looking into a new eye drop called cenegermin to treat a persistent sore on the front of the eye (cornea). Researchers want to see if it helps the sore heal better and if it's safe compared to a dummy treatment. It involves different treatment and follow-up periods.
Persistent Corneal Epithelial DefectCzechia - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Czechia - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisCzechia - Active not recruitingPHASE3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.
NeoplasmsCzechia - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaCzechia - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerCzechia - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
Metastatic Colorectal CancerCzechia - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Czechia - RecruitingPHASE3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study looks at a new medicine, NNC0487-0111, for people with heart failure and obesity. It compares the medicine to a dummy treatment (placebo) to see if it's safe and helps improve heart health.
ObesityHeart FailureCzechia - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
Immunoglobulin A NephropathyCzechia - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisCzechia - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisCzechia - RecruitingPHASE3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
This study looks at a medicine called vedolizumab for children and teenagers with moderate to severe Crohn's disease. It aims to see if the medicine can make their symptoms better and heal inflammation in their gut.
Crohn's Disease (CD)Czechia - RecruitingPHASE4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
This study looks at how well a medicine called pegcetacoplan works and if it's safe for people in the UK with rare kidney diseases like C3G or IC-MPGN. It uses real-life information from patients to help doctors make better decisions about treatment.
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Czechia - RecruitingPHASE2, PHASE3
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
This study is testing a new medicine, efgartigimod PH20 SC, for children aged 2 to 17 with a muscle weakness condition called generalised Myasthenia Gravis. We want to find the best dose and make sure it's safe. Participants will get injections and be monitored.
Generalized Myasthenia GravisCzechia - Active not recruitingPHASE3
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
This study looks at the long-term safety of a new medicine, PTC923, for people with Phenylketonuria (PKU). It also checks if the medicine helps people eat more varied foods by seeing if their usual diet and protein intake change over time.
PhenylketonuriaCzechia - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaCzechia - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaCzechia - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
Myelodysplastic Syndrome (MDS)Czechia - Active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
Lymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-cellGraft Vs Host DiseaseCzechia - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
Carcinoma, Renal CellCzechia - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionCzechia - RecruitingPHASE3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Duvakitug for people with Crohn's disease that isn't well controlled. It compares Duvakitug to a dummy medicine to see if it's safe and effective in improving symptoms for those with moderately to severely active Crohn's.
Crohn's DiseaseCzechia - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightCzechia - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseCzechia - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerCzechia - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseCzechia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseCzechia - RecruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
Non-small Cell CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung CarcinomaCzechia - Not yet recruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseCzechia - Active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
Solid TumorsCzechia - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
This study is testing a new medicine called empasiprubart for adults with a nerve condition called CIDP. It wants to see if the medicine is safe and helps people feel better. Participants will get the study medicine or a dummy medicine first, then everyone will get the study medicine.
Chronic Inflammatory Demyelinating PolyneuropathyCIDPChronic Inflammatory Demyelinating PolyradiculoneuropathyCzechia - Active not recruitingPHASE3
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
This study is looking at a new medicine called vutrisiran for people with a heart condition called transthyretin amyloidosis (ATTR) cardiomyopathy. It aims to see if the medicine can help improve the condition and if it's safe compared to a dummy treatment.
Transthyretin Amyloidosis (ATTR) With CardiomyopathyCzechia - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Czechia - RecruitingPHASE3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, riliprubart, against the usual treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It's for adults already receiving IVIg to see if riliprubart works safely and effectively to manage their condition.
Chronic Inflammatory Demyelinating PolyneuropathyCzechia - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Czechia - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
Renal Cell CarcinomaCzechia